Cannabis Law Report

AUGUST 27, 2021

The Board will advise Delic and its subsidiaries, including Ketamine Infusion Centers, Delic Labs and others, as they develop safety protocols and best practices pertaining to legal psychedelic wellness treatments today and those legalized in the future. Chris Ray , PhD : Interventional Pain Physician. About Delic Corp, Inc.

Research and Development 98

Research and Development Treatment Media Medicine 98

Cannabis Law Report

JANUARY 23, 2022

Multivariate analysis of overall survival and nonrelapse mortality (NRM) data has shown GVHD likelihood can be impacted by age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count (Arora et al. Implications.

Research and Development 52

Research and Development Wellness and Beauty Patients CBD 52

Cannabis Law Report

APRIL 8, 2022

MAPS continued to publish Bulletin articles about MDMA research , requests for donations , and discontinuing animal studies. The FDA formally decided to open the door to psychedelic research in human participants, and later accepted MAPS’ Phase 1 MDMA safety and tolerance study protocol. MAPS Founder Rick Doblin, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 4, 2021

He has also donated significant sums of money to several different research centers and non-profits, and has influenced the funding of several large psychedelics initiatives. Through its discovery platform, Delix has identified a class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51